Morpholino Database

Search By For Use * as a wildcard character (e.g. "BMP*"). For Tips on search see Search FAQs.

Morpholino Summary

General Information

Morpholino name:

SC5003-control

Morpholino sequence:

CCCAAATAACCCACTGACTGATACC
Find in Genbank

Target name:

AI883960

Target sequence: (Morpholino Target and ATG)
Search in Genbank Search in Ensembl

GCCAGTCGGCTGGACAGACACAAGAGGAGCTTTTCGCGGGTTTATTGGGTGACTGACTATGGCAAGCCG GTCCAACTGTTTTTACTGTCGTGAGGACCTCAGTGGAAAGAAGTTCGTGAGGAAAGACGAGAAACAAGTC TGTGTGCGATGCTTCGACAAGTTCTGCGCAAACACCTGCACAGAGTGTCGACGCACGATCAGCACGGACT CCAAGGAGCTTCACCATAAGGGGAAATACTGGCACTCTGATTGTTTCCGATGTGCCAAGTGCTATAAGAA TCTGGCCAAGGAGTCTTTCACCTCCAAAGATGACAGGATCCTGTGTGGGACGTGTAGCTCACGTGAGGAC GCTCCTCGCTGCCATGGCTGCTACAAGCCCATACTGCCAGGCACTGAGAATGTGGAATACAAAGGCAACT CATGGCACGATGAGTGTTTCAAATGCTATCAGTGTCAAAAGCCAATCGGCAACAAGAGTTTCATAACAAA GAACAACAATGTCTACTGCAGCCCTTGCCATGAGAAGAAATTTGCCAAACAGTGTGCTTGCTGTAAGAAG CCCATTACCACAGGAGGTGTGAATTACCAGGACCAGCCGTGGCATTCAGAGTGCTTTGTGTGCTCCTCCT GCCGAAAGCCTCTGGCGGGCACCCGCTTTACCTCCCACGAGGAGAAAGTCTACTGTGTGGACTGCTATAA AAGCACTGTGGCCAAAAAATGCAGCGGTTGCCAGAACCCCATTACAGGATTTGGCAAGGCTACGAATGTA GTGAACTACGAGGGTGGCTCTTGGCATGATTACTGCTTCAACTGTAAGAAATGCTCCCTCAACCTGGCCG ACAAGCGCTTTGTTGCTCACAGCGGACACATTTACTGCTCCGACTGCTCCAAGAAACTGTAAACACTCAG AAGAGGGAGATTACTTTAGAAAAATATCAGCCTTCTTTTGAATTTATACAAAAATCCCACATAAAAATGT TGAAGTATTGACAAAGGCTTCTGTTGTGTTGATTCTGGCAGCTTTTTGAGGGGAGTTTGATGTTTCCTGT GAGGAATGTTTCGTTTACCTTGAGGCTTTGATAGGAAAACTTATCCTCTCTTTTTCCAATGACCCATTTG TCTCAGGAAAGATAGTAGGGCGGGAAGAAAGACAGATAGTAAAATAAGTGTTTTTGAGAATGTGAAGCCT GTTTTTGAGATGTATTGATCTTTCATTTCACATTTCATGATGCCAAATAAAGCTTTGGGTTGGTAACTTT TAGCCTATAATCATGACCAATGAATATTTCAGTGATTCAGCAAATTCCTTTCAAGATACTTTCATATAAA ATACCATACTGGAAAATTAAAGTGTGTAGGTTTTGTCTGTCTCCTTACTTATACGTTATCGTTAATGCAA TTAACATGAATAATCCATTTTCATTTCTTTGTATAAACTGAAAAATAAAGTTAAGTATCTGAGAAATCTG AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

Gene targeted:
AI883960
Find in ZFIN Find in Pubmed
All the morpholinos targets to the gene

Synonyms:

Comments:

Reference:

Survival Curve:	Normality Curve:

Note: When more than one data point existed per dose an average was used. p53 morpholino co-injections were used to minimize non-specific toxicity effects (Robu et al. PLoS Genetics 2007)

Screens Performed (number of tests):	Defects Observed:
Blood: (12) PAX2: (1) Eye: (3)	- eye absent (33.33%, dose:4.5ng, p53:ng, days: Day: 3) - eye dysplastic (11.11%, dose:4.5ng, p53:ng, days: Day: 3) - eye small size (44.44%, dose:4.5ng, p53:ng, days: Day: 3)

Images